Commentary & Perspectives

The New Blueprint for Vaccine Development

ReiThera’s leaders discuss platform technologies, scalable manufacturing, and the trust needed to strengthen global vaccine preparedness

  • By

  • March 12, 2026

  • 6 min

Share

  • 1

    Vaccine development is transitioning to platform-based technologies.

  • 2

    Speed and quality are critical in vaccine manufacturing.

  • 3

    The COVID-19 pandemic showed vulnerabilities in supply chains.

  • 4

    Trust and transparency are critical in combating anti-vaccine rhetoric.

  • 5

    International collaboration is essential for overcoming global health challenges.

  • 6

    Current trends include mRNA and viral vector technologies.

  • 7

    Preparedness requires adaptable manufacturing processes.

Original Source(s)

The New Blueprint for Vaccine Development

ReiThera’s leaders discuss platform technologies, scalable manufacturing, and the trust needed to strengthen global vaccine preparedness

  • March 12, 2026

  • 6 min

Related Content

The 60 Percent Diagnostic Gap in M/E

What earlier mNGS testing could mean for labs and clinicians

Study Maps US States Most Vulnerable to Flu

Machine learning analysis identifies 11 jurisdictions—including the District of Columbia, Massachusetts, and Hawaii—with the highest vulnerability to influenza-like illness.

Which Viruses Hit Kids Hardest?

Study compares pathogen type, comorbidities, and clinical severity in pediatric admissions